ENP63: Vosoritide and Children With Genetic Short Stature

We look at Vosoritide, a promising, potential treatment for children with genetic short stature who do not have chondrodysplasia. Host Aaron Lohr talks with Andrew Dauber, MD, division chief of endocrinology at Children’s National Hospital. Dr. Dauber and colleagues presented about Vosoritide at ENDO 2022. Their abstract is titled, “A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature.” Show notes are available at https://www.endocrine.org/podcast/enp63-vosoritide-and-children-with-genetic-short-stature — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast